Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

NCT ID: NCT03327857

Last Updated: 2023-01-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-31
• Study Completion Date: 2022-12-31

Brief Summary

A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)

Detailed Description

Neihulizumab (ALTB-168) is an immune checkpoint agonist antibody that regulates T cell homeostasis. The unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death preferentially in late-stage activated T cells without affecting resting T cells and early-activated T cells. Because pathogenic T cells underlying the inflammatory conditions are usually in late-stage activated state, eliminating this population of cells can potentially result in controlling autoimmune inflammation of T cell associated diseases, such as GvHD.

Conditions

Steroid-refractory Acute Graft-versus-Host Disease; Treatment-refractory Acute Graft-versus-Host Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neihulizumab (ALTB-168)

Intravenous doses of Neihulizumab (ALTB-168)

Group Type: EXPERIMENTAL

Neihulizumab (ALTB-168)

Intervention Type: BIOLOGICAL

Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.

Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks.

Interventions

Neihulizumab (ALTB-168)

Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.

Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Patients must have clinical aGVHD and pathologic findings consistent with the diagnosis by biopsy of at least 1 involved site, and

1. progressed after 3 days of treatment with methylprednisolone (MP) 2 mg/kg/day equivalent, or

2. did not improve after 7 days of treatment with MP 2 mg/kg/day equivalent, or

3. progressed to involve a new organ after treatment with MP 1 mg/kg/day equivalent for skin and upper gastrointestinal (GI) GVHD, or

4. recurred during or after a steroid taper

2. For single dose phase: Patients must have erythematous manifestations of cutaneous aGVHD. Characteristics of the rash must indicate active inflammation (red coloration) as distinct from resolving inflammation (brown coloration).

3. For single dose phase: Providers and patients must be willing to defer new systemic or cutaneous topical treatment of aGVHD for at least 36 hr after administration of Neihulizumab.

4. Patient must give informed consent and sign an approved consent form prior to any study procedures.

5. Females of childbearing potential must have a negative pregnancy test result before enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study for at least 30 days after enrollment in the study.

Exclusion Criteria

1. For single dose phase: Prior administration of anti-lymphocyte globulin or anti- thymocyte globulin for treatment of aGVHD.

2. For multiple dose phase: Has received any systemic treatment in addition to corticosteroids for aGVHD.

3. Stage 4 lower GI GVHD, defined by the presence of ileus, severe abdominal pain, or overt GI bleeding.

4. Uncontrolled infections not responding to antimicrobial therapy or requiring intensive critical care or vasopressors.

5. Evidence of end-organ cytomegalovirus (CMV) or adenovirus infection.

6. Known to have adenovirus, or Epstein Barr virus (EBV) viremia from screening according to institutional standard practice. Patients receiving appropriate antiviral treatment for CMV, HHV6 or hepatitis viremia are eligible on a case-by-case basis.

7. HIV infection or a known HIV-related malignancy.

8. Tuberculosis, history of tuberculosis or a known positive Quantiferon test for tuberculosis.

9. Unplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed.

10. Known relapsed or progressive malignancy after transplant, posttransplant lymphoproliferative disease or any secondary malignancy diagnosed after HCT.

11. Absolute neutrophil count (ANC) <1000/mm3.

12. Total serum bilirubin concentration >3.0 mg/dL UNLESS attributed to GVHD.

13. Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault equation.

14. Sodium (Na) concentration < 130 mmol/L.

15. Karnofsky Performance Status (KPS) or Lansky Performance Status < 20%.

16. Intensive care unit (ICU) care, life expectancy of less than 28 days, ongoing or unresolved hepatic sinusoidal obstruction syndrome, unstable hemodynamics, or evidence of current or previous clinically significant disease, medical condition or finding (including vital signs and ECG) that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

17. History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients.

18. Pregnancy or nursing.

19. Less than 12 years of age.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AltruBio Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shih-Yao Lin, MD, PhD

Role: STUDY_DIRECTOR

AltruBio, Inc. (formerly AbGenomics International)

Paul Martin, MD

Role: PRINCIPAL_INVESTIGATOR

Fred Hutchinson Cancer Center

Locations

City of Hope

Duarte, California, United States

David Geffen School of Medicine at UCLA

Los Angeles, California, United States

University of Miami - Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Emory University

Atlanta, Georgia, United States

University of Chicago

Chicago, Illinois, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

Dana Farber Cancer Center

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

University of Minnesota

Minneapolis, Minnesota, United States

University Hospitals Seidman Cancer Center

Cleveland, Ohio, United States

Baylor College of Medicine-Houston Methodist & Texas Children's Hospital

Houston, Texas, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Countries

United States

Other Identifiers

2017.002.01

Identifier Type: -

Identifier Source: org_study_id